Progress in targeted signaling inhibition and immunotherapy has spurred a race to transform treatment across virtually all cancer disease sites. There is ample preclinical data pointing toward the ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...